Company intelligence / Profile preview

CardioCell LLC

San Diego, California, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

CardioCell has completed a Phase IIa clinical trial for chronic heart failure using itMSCs delivered intravenously, showing safety and improvements in patient well-being. The trial demonstrated statistically significant improvements in the 6-minute walk test and KCCQ Clinical Summary score, as well as reduction in inflammation markers. The company planned to proceed with Phase IIb trials based on these promising results[4][7].

Therapeutic areas: Cardiovascular
Modalities: Ischemia-tolerant mesenchymal stem cells (itMSCs)allogeneic stem cells
Industry: Biotech

Drug pipeline

1 asset

CardioCell

Unknown

Partnerships

MedStar Heart & Vascular InstituteMedStar Health

Beyond the preview

Go deeper on CardioCell LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardioCell LLC.

Explore the full profile